There is increasing data in favour of follicle-stimulating hormone (FSH) therapy in patients\nwith oligo-asthenozoospermia and normal-range gonadotropins in order to increase sperm count\nand above all sperm motility. Some studies showed an improvement in DNA fragmentation and\nspontaneous pregnancy. Recently, biosimilar FSH has been marketed with the same indications. We\nperformed a retrospective multicentric case-control study involving 147 asthenozoospermic patients\nbetween 18 and 45 years of age. A total of 97 patients were treated with biosimilar FSH 150 UI three\ntimes a week for 3 months, while 50 control subjects received no treatment. Patients were evaluated\nat baseline and after 3 months with semen analysis including DNA fragmentation, testicular colour\nDoppler ultrasound, and blood tests. Spontaneous pregnancies were recorded during a further\nfollow-up period of 6 months. Treated patients showed after treatment a statistically significant\nincrease in sperm concentration, total sperm count, and total motile sperm, as well as improved\nprogressive motility and non-progressive motility. DNAfragmentation showed a significant reduction.\nConversely, in the control group, no significant change was found. Pregnancy rate was significantly\nhigher in treated patients. These data suggest comparable effcacy of biosimilar FSH in the treatment\nof male infertility; however, larger studies are needed to confirm our results.
Loading....